Objectives of the ANRS 0629s DEMELE-JEV study
Primary endpoint
Incidence of Japanese Encephalitis Virus infection in both participant groups based on laboratory confirmation (PCR positivity, seroconversion, or 4 fold antibody rising based on ELISA results, with confirmatory testing by virus neutralization assays).
Secondary endpoints
- To estimate the anti-JEV seropositivity rate in children attending Kantha Bopha hospitals in Phnom Penh and Siem Reap for different age groups.
- To describe the influence of dengue immunity on the epidemiological, clinical, and biological characteristics of JEV infection (cohorts 1 and 2).
- To develop new tools (Luminex serology) for diagnosis of JEV infection
- To develop evaluate new tools (QUIASTAT) for diagnosis of meningitis and encephalitis infection in Cambodia
- To model anti-JEV antibody kinetics over time following natural infection and vaccination (cohorts 1 and 2).
- Using mathematical modeling of antibody titers, to quantify DENV and JEV interaction, e.g., to estimate the reduction of the risk of JEV infection following DENV infection.